|
Match
|
Document |
Document Title |
|
|
7378094 |
Therapeutic uses of complement receptor 2
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
|
|
|
7375194 |
Antibodies that bind to an epitope on the Huntington's disease protein
The present invention relates generally to the generation and characterization of anti-huntingtin antibodies binding an epitope on the Huntington's disease protein. The invention further relates to...
|
|
|
7371382 |
Methods of inhibiting αvβ3-mediated binding with αvβ3-specific antibodies
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to α V β 3 , or a functional fragment thereof. The invention also provides nucleic acid molecules...
|
|
|
7371825 |
Anti-MCP-1 antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-MCP-1 antibodies, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic...
|
|
|
7371377 |
Antibodies to polypeptides homologous to VEGF and BMP1
The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor...
|
|
|
7371817 |
PRO9783 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7371816 |
PRO10284 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7368111 |
Human antibodies specific for TGFβ2
Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGFβ) bind specifically isoforms TGFβ2 and TGFβ1 or both,...
|
|
|
7368535 |
CD200 receptors
The present invention relates to CD200 receptor isoforms and modulators thereof and their use in methods of immune modulation and pharmaceutical compositions.
|
|
|
7368114 |
Fusion protein including of CD4
Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a...
|
|
|
7368543 |
Diagnosis and treatment of hepatic disorders
The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration...
|
|
|
7364865 |
Antibodies to myeloid progenitor inhibitory factor-1 (MPIF-1)
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3...
|
|
|
7364737 |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also...
|
|
|
7364735 |
Method for diagnosis and treatment of haemophilia A patients with an inhibitor
A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody for...
|
|
|
7365166 |
Anti-VEGF antibodies
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of...
|
|
|
7364731 |
Polypeptide variants
A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326,327, 329, 331, 333...
|
|
|
7364736 |
Antibodies to OPGL
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are...
|
|
|
7364738 |
Monoclonal antibodies to the CLFA protein and method of use in treating infections
Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus , including the active...
|
|
|
7365168 |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues...
|
|
|
7365156 |
PRO1316 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7361338 |
Methods to inhibit growth of prostate cancer cells
A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7361732 |
PRO4400 polypeptides
The present invention is directed to novel polypeptide and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7361344 |
Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke
A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective...
|
|
|
7361341 |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the treatment of cancers and other...
|
|
|
7357927 |
Death domain containing receptors
The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated...
|
|
|
7358054 |
Antibodies to VLA-1
Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by...
|
|
|
7358339 |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7355008 |
Identification and engineering of antibodies with variant Fc regions and methods of using same
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises...
|
|
|
7354584 |
Recombinant IL-9 antibodies
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and...
|
|
|
7355007 |
Antibodies that bind PRO5005 Polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7355012 |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and...
|
|
|
7355011 |
Biological products
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein...
|
|
|
7354999 |
PRO1481 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7355018 |
Modified IGF1 polypeptides with increased stability and potency
A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an...
|
|
|
7354585 |
Methods of treating coagulapathic or thrombotic disorders
The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention...
|
|
|
7355013 |
PRO6017 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7354586 |
Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
7351816 |
Nucleic acid encoding anti-IgE antibodies
The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including...
|
|
|
7351803 |
CD16A binding proteins and use for the treatment of immune disorders
CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for...
|
|
|
7351804 |
Antibodies against PRO4421
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7351583 |
Antibodies to G protein-coupled receptor
A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors...
|
|
|
7351796 |
PRO9904 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7348405 |
PRO10274 polypeptides
The present invention is directed to PRO10013 polypeptides.
|
|
|
7342110 |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced...
|
|
|
7342098 |
PRO1154 polypeptide
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7341722 |
Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
|
|
|
7342104 |
Antibodies against the PRO4320 polypeptide
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7338660 |
Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also...
|
|
|
7339035 |
Antibody recognizing GM1 ganglioside-bound amyloid β-protein and DNA encoding the antibody
It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid...
|
|
|
7339034 |
PRO1305 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|